Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment

Larry R. Kirkland, Margaret A Fischl, Karen T. Tashima, David Paar, Thomas Gensler, Neil M. Graham, Haitao Gao, Jacqueline R. Carranza Rosenzweig, Daniel R. McClernon, Ginger Pittman, Siegrid M. Hessenthaler, Jaime E. Hernandez

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Prison inmates with human immunodeficiency virus (HIV) infection can be difficult to treat because of the complexity and intrusiveness of many combination antiretroviral therapy regimens. NZTA4007, a 24-week open-label, single-arm clinical trial involving 108 antiretroviral therapy-naive, incarcerated, HIV-infected persons, was conducted to evaluate a compact regimen (4 tablets per day) consisting of 1 lamivudine-zidovudine (150 mg/300 mg) combination tablet (COM) and one 300-mg abacavir tablet administered twice daily under directly observed treatment conditions. In the intent-to-treat observed analysis, the plasma HIV type 1 (HIV-1) RNA level remained at ≤400 copies/mL in 85% of the patients and at <50 copies/mL in 75% of the patients. Median change from baseline was -2.41 log10 copies/mL for the HIV-1 RNA level and +111 cells/mm3 for the CD4 cell count. The overall adherence to prescribed doses was 94% for patients who remained enrolled in the study. COM-abacavir given twice daily was generally well tolerated, and adverse events prompted only 4 patients to withdraw from the study.

Original languageEnglish
Pages (from-to)511-518
Number of pages8
JournalClinical Infectious Diseases
Volume34
Issue number4
DOIs
StatePublished - Feb 15 2002

Fingerprint

Lamivudine
Zidovudine
Virus Diseases
Tablets
HIV
HIV-1
RNA
Prisons
Therapeutics
CD4 Lymphocyte Count
Clinical Trials
abacavir

ASJC Scopus subject areas

  • Immunology

Cite this

Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. / Kirkland, Larry R.; Fischl, Margaret A; Tashima, Karen T.; Paar, David; Gensler, Thomas; Graham, Neil M.; Gao, Haitao; Carranza Rosenzweig, Jacqueline R.; McClernon, Daniel R.; Pittman, Ginger; Hessenthaler, Siegrid M.; Hernandez, Jaime E.

In: Clinical Infectious Diseases, Vol. 34, No. 4, 15.02.2002, p. 511-518.

Research output: Contribution to journalArticle

Kirkland, LR, Fischl, MA, Tashima, KT, Paar, D, Gensler, T, Graham, NM, Gao, H, Carranza Rosenzweig, JR, McClernon, DR, Pittman, G, Hessenthaler, SM & Hernandez, JE 2002, 'Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment', Clinical Infectious Diseases, vol. 34, no. 4, pp. 511-518. https://doi.org/10.1086/338400
Kirkland, Larry R. ; Fischl, Margaret A ; Tashima, Karen T. ; Paar, David ; Gensler, Thomas ; Graham, Neil M. ; Gao, Haitao ; Carranza Rosenzweig, Jacqueline R. ; McClernon, Daniel R. ; Pittman, Ginger ; Hessenthaler, Siegrid M. ; Hernandez, Jaime E. / Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. In: Clinical Infectious Diseases. 2002 ; Vol. 34, No. 4. pp. 511-518.
@article{320e0671f2524fa99756fbd395392b1c,
title = "Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment",
abstract = "Prison inmates with human immunodeficiency virus (HIV) infection can be difficult to treat because of the complexity and intrusiveness of many combination antiretroviral therapy regimens. NZTA4007, a 24-week open-label, single-arm clinical trial involving 108 antiretroviral therapy-naive, incarcerated, HIV-infected persons, was conducted to evaluate a compact regimen (4 tablets per day) consisting of 1 lamivudine-zidovudine (150 mg/300 mg) combination tablet (COM) and one 300-mg abacavir tablet administered twice daily under directly observed treatment conditions. In the intent-to-treat observed analysis, the plasma HIV type 1 (HIV-1) RNA level remained at ≤400 copies/mL in 85{\%} of the patients and at <50 copies/mL in 75{\%} of the patients. Median change from baseline was -2.41 log10 copies/mL for the HIV-1 RNA level and +111 cells/mm3 for the CD4 cell count. The overall adherence to prescribed doses was 94{\%} for patients who remained enrolled in the study. COM-abacavir given twice daily was generally well tolerated, and adverse events prompted only 4 patients to withdraw from the study.",
author = "Kirkland, {Larry R.} and Fischl, {Margaret A} and Tashima, {Karen T.} and David Paar and Thomas Gensler and Graham, {Neil M.} and Haitao Gao and {Carranza Rosenzweig}, {Jacqueline R.} and McClernon, {Daniel R.} and Ginger Pittman and Hessenthaler, {Siegrid M.} and Hernandez, {Jaime E.}",
year = "2002",
month = "2",
day = "15",
doi = "10.1086/338400",
language = "English",
volume = "34",
pages = "511--518",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment

AU - Kirkland, Larry R.

AU - Fischl, Margaret A

AU - Tashima, Karen T.

AU - Paar, David

AU - Gensler, Thomas

AU - Graham, Neil M.

AU - Gao, Haitao

AU - Carranza Rosenzweig, Jacqueline R.

AU - McClernon, Daniel R.

AU - Pittman, Ginger

AU - Hessenthaler, Siegrid M.

AU - Hernandez, Jaime E.

PY - 2002/2/15

Y1 - 2002/2/15

N2 - Prison inmates with human immunodeficiency virus (HIV) infection can be difficult to treat because of the complexity and intrusiveness of many combination antiretroviral therapy regimens. NZTA4007, a 24-week open-label, single-arm clinical trial involving 108 antiretroviral therapy-naive, incarcerated, HIV-infected persons, was conducted to evaluate a compact regimen (4 tablets per day) consisting of 1 lamivudine-zidovudine (150 mg/300 mg) combination tablet (COM) and one 300-mg abacavir tablet administered twice daily under directly observed treatment conditions. In the intent-to-treat observed analysis, the plasma HIV type 1 (HIV-1) RNA level remained at ≤400 copies/mL in 85% of the patients and at <50 copies/mL in 75% of the patients. Median change from baseline was -2.41 log10 copies/mL for the HIV-1 RNA level and +111 cells/mm3 for the CD4 cell count. The overall adherence to prescribed doses was 94% for patients who remained enrolled in the study. COM-abacavir given twice daily was generally well tolerated, and adverse events prompted only 4 patients to withdraw from the study.

AB - Prison inmates with human immunodeficiency virus (HIV) infection can be difficult to treat because of the complexity and intrusiveness of many combination antiretroviral therapy regimens. NZTA4007, a 24-week open-label, single-arm clinical trial involving 108 antiretroviral therapy-naive, incarcerated, HIV-infected persons, was conducted to evaluate a compact regimen (4 tablets per day) consisting of 1 lamivudine-zidovudine (150 mg/300 mg) combination tablet (COM) and one 300-mg abacavir tablet administered twice daily under directly observed treatment conditions. In the intent-to-treat observed analysis, the plasma HIV type 1 (HIV-1) RNA level remained at ≤400 copies/mL in 85% of the patients and at <50 copies/mL in 75% of the patients. Median change from baseline was -2.41 log10 copies/mL for the HIV-1 RNA level and +111 cells/mm3 for the CD4 cell count. The overall adherence to prescribed doses was 94% for patients who remained enrolled in the study. COM-abacavir given twice daily was generally well tolerated, and adverse events prompted only 4 patients to withdraw from the study.

UR - http://www.scopus.com/inward/record.url?scp=0037083022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037083022&partnerID=8YFLogxK

U2 - 10.1086/338400

DO - 10.1086/338400

M3 - Article

C2 - 11797179

AN - SCOPUS:0037083022

VL - 34

SP - 511

EP - 518

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -